Skip to content

Robotic Therapy and Brain Stimulation in the Early Phase After Stroke

Effects of Robotic Therapy and Transcranial Direct Current Stimulation on Motor Performance of the Paretic Upper Limb in the Early Phase After Stroke

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03230695
Enrollment
24
Registered
2017-07-26
Start date
2017-08-03
Completion date
2025-07-31
Last updated
2022-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, robotic therapy, transcranial direct current stimulation

Brief summary

Stroke is the second cause of death worldwide and the majority of the survivors remain with motor impairments. Inhibition of the motor cortex of the unaffected hemisphere has emerged as a potential intervention to enhance effects of other rehabilitation strategies on improvement of motor performance of the paretic upper limb. In this proof-of-concept study we will evaluate the effects of inhibition of the motor cortex of the unaffected hemisphere associated with robotic therapy on improvement of motor performance of the paretic upper limb in the early phase post-stroke.

Detailed description

The main goal of this study is to test the proof of concept of benefits of inhibition of the motor cortex of the unaffected hemisphere on learning evaluated by improvement in kinematics of motor performance, in patients with upper limb paresis in the early phase post-stroke. For this purpose, patients will be randomized to receive real or sham transcranial direct current stimulation before a session of robotic therapy. Data will be collected by kinematic assessment performed automatically by the robot at baseline, immediately after and 24h after the intervention. The working hypothesis is that one session of upper limb motor training will lead to improvement of performance in metrics of kinematics, and this improvement will be maintained up to 24h after the end of the training.

Interventions

Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.

Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).

DEVICESham stimulation

In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.

Sponsors

Conselho Nacional de Desenvolvimento Científico e Tecnológico
CollaboratorOTHER_GOV
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Ischemic or hemorrhagic stroke onset from 3 days to 9 weeks before, confirmed by computed tomography or magnetic resonance imaging. Motor impairment of an upper limb, defined as a score between 1 - 3 in the Medical Research Council Scale, for at lest one the following movements: elbow extension, shoulder flexion, or shoulder extension. Ability to provide written informed consent. Ability to comply with the schedule of interventions and evaluations in the protocol.

Exclusion criteria

Severe spasticity at the paretic elbow, wrist or fingers, defined as a score of \> 3 in the Modified Ashworth Spasticity Scale. No active shoulder and elbow movements Uncontrolled medical problems such as end-stage cancer or renal disease Pregnancy Potential contraindications to transcranial direct current stimulation: history of seizures, lesions on the scalp, intracranial metal implants, prior intracranial surgery, use of drugs that interfere on cortical excitability (such as antiepileptic drugs, benzodiazepines) Other neurological disorders such as Parkinson's disease Psychiatric illness Aphasia or severe cognitive deficits that compromise comprehension of the experimental protocol or ability to provide consent. Hemineglect Cerebellar lesions or on cerebellar pathways Contact precautions

Design outcomes

Primary

MeasureTime frameDescription
Movement SmoothnessKinematic assessment at baseline, immediately after intervention; and 24h after.The speed shape, calculated as mean speed divided by peak speed.

Secondary

MeasureTime frameDescription
Number of peaks of the movementkinematic assessment at baseline, immediately after intervention; and 24h after.Number of peaks of the movement is calculated as the negative of the number of peaks in the speed profile.
Jerk metric of the movementkinematic assessment at baseline, immediately after intervention; and 24h afterJerk metric of the movement is calculated by dividing the negative mean jerk magnitude by the peak speed.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026